CD274 and esophageal squamous cell carcinoma: Notably, the benefit of adding pembrolizumab to chemotherapy is confined to EAC and ESCC with a PD-L1 CPS ≥ 10 (51% of patients) with a HR 0.62 (95% CI 0.49–0.78); p < 0.0001), whereas patients with a CPS < 10 (47% of patients) do not benefit with statistical significance (HR 0.86 (95% CI 0.68–1.10)).